Why the study?
What are the major cardiovascular complications associated with modern anticancer drugs, and what are the current strategies for their diagnosis, treatment, and prevention?
What are the major cardiovascular complications associated with modern anticancer drugs, and what are the current strategies for their diagnosis, treatment, and prevention?
Modern cancer therapies, particularly targeted agents, are associated with significant cardiovascular toxicities that necessitate dedicated cardio-oncology collaboration.
Answers are grounded in this paper and cite their sources.
Supports heightened vigilance for CV toxicities with targeted cancer therapies; leaves open standardized management guidelines.
Recent advances in chemotherapy have substantially improved the prognosis of cancer patients. However, many anticancer drugs, especially newly developed ;molecular-target drugs', such as the anti-HER2 blocking antibody and the anti-vascular endothelial growth factor antibody, have serious cardiovascular side-effects such as heart failure, thromboembolism, severe hypertension and lethal arrhythmia, which interrupt cancer treatment and decrease the patient's quality of life. Despite the increasing clinical significance, cardiologists have not been focusing enough of their attention on this issue. The major cardiovascular complications associated with anticancer drugs, and current diagnosis, treatment and prevention strategies are reviewed. Close collaborations between oncologists and cardiologists is necessary to tackle cardiovascular complications and advance cancer treatment.
No takes yet. Share an insight, caveat, or question.
Minami et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: